Shopping Cart
- Remove All
Your shopping cart is currently empty
GSK163090 is a specific and orally active 5-HT1A/B/D receptor antagonist (pKis: 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $31 | In Stock | |
| 2 mg | $44 | In Stock | |
| 5 mg | $73 | In Stock | |
| 10 mg | $127 | In Stock | |
| 25 mg | Preferential | In Stock | |
| 50 mg | Preferential | In Stock | |
| 1 mL x 10 mM (in DMSO) | $79 | In Stock |
| Description | GSK163090 is a specific and orally active 5-HT1A/B/D receptor antagonist (pKis: 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3). |
| Targets&IC50 | 5-HT6 receptor (human):<5.3 (pKi), D2 Receptor:6.3 (pKi), 5-HT2A receptor:6 (pKi), 5-HT1A:9.4 (pKi), 5-HT1B:8.5 (pKi), 5-HT2B receptor:6.3 (pKi), 5-HT1D:9.7 (pKi), 5-HT2C receptor:5.8 (pKi), 5-HT7 receptor (human):6.8 (pKi), D3 receptor:6.7 (pKi) |
| In vitro | GSK163090 demonstrates clear dose-dependent inhibition of the 8-OH-DPAT-induced hyper locomotor activity (hLMA), with ED50 values ranging from 0.03 to 1 mg/kg. GSK163090 was devoid of agonist activity at R1 receptors, but rather it demonstrated a moderate functional antagonism of the phenylephrine-induced contraction of rabbit aorta (pIC50: 6.9). |
| In vivo | The superior quality of GSK163090 was further highlighted by its commendable in vivo pharmacokinetic profile in rats and its outstanding activity in the 5-HT1A PD model, where 50% efficacy was achieved at a blood concentration of 3 ng/mL. |
| Molecular Weight | 415.53 |
| Formula | C25H29N5O |
| Cas No. | 844903-58-8 |
| Smiles | Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1 |
| Relative Density. | 1.216 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 14.29 mg/mL (34.39 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.41 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.